Log in

NASDAQ:KURAKura Oncology News Headlines

$8.14
+0.19 (+2.39 %)
(As of 04/5/2020 04:00 PM ET)
Add
Compare
Today's Range
$7.69
Now: $8.14
$8.26
50-Day Range
$6.45
MA: $10.47
$12.60
52-Week Range
$6.35
Now: $8.14
$21.42
Volume460,004 shs
Average Volume472,072 shs
Market Capitalization$369.80 million
P/E RatioN/A
Dividend YieldN/A
Beta2.05

Headlines

Kura Oncology (NASDAQ KURA) News Headlines

Source:
DateHeadline
Kura Oncology Inc (NASDAQ:KURA) Expected to Announce Earnings of -$0.42 Per ShareKura Oncology Inc (NASDAQ:KURA) Expected to Announce Earnings of -$0.42 Per Share
www.americanbankingnews.com - March 25 at 11:06 PM
Kura Oncology (KURA) Presents At Cowen and Compnay Health Care Conference - SlideshowKura Oncology (KURA) Presents At Cowen and Compnay Health Care Conference - Slideshow
seekingalpha.com - March 17 at 6:24 PM
Kura Oncology Inc (NASDAQ:KURA) Receives Consensus Rating of "Buy" from BrokeragesKura Oncology Inc (NASDAQ:KURA) Receives Consensus Rating of "Buy" from Brokerages
www.americanbankingnews.com - March 14 at 2:18 AM
BRIEF-Kura Oncology Receives Fast Track Designation For Tipifarnib In T-Cell LymphomasBRIEF-Kura Oncology Receives Fast Track Designation For Tipifarnib In T-Cell Lymphomas
www.reuters.com - March 3 at 10:28 PM
Kura Oncologys tipifarnib Fast Trackd for T-cell lymphomasKura Oncology's tipifarnib Fast Track'd for T-cell lymphomas
seekingalpha.com - March 3 at 12:27 PM
Kura Oncology Receives Fast Track Designation for Tipifarnib in T-Cell LymphomasKura Oncology Receives Fast Track Designation for Tipifarnib in T-Cell Lymphomas
finance.yahoo.com - March 3 at 12:27 PM
Edited Transcript of KURA earnings conference call or presentation 25-Feb-20 9:30pm GMTEdited Transcript of KURA earnings conference call or presentation 25-Feb-20 9:30pm GMT
finance.yahoo.com - February 26 at 9:09 AM
Kura Oncology Reports Fourth Quarter and Full Year 2019 Financial ResultsKura Oncology Reports Fourth Quarter and Full Year 2019 Financial Results
finance.yahoo.com - February 25 at 6:13 PM
Kura Oncology to Participate in Three Upcoming Investor ConferencesKura Oncology to Participate in Three Upcoming Investor Conferences
finance.yahoo.com - February 19 at 6:01 PM
Kura Oncology to Report Fourth Quarter and Full Year 2019 Financial ResultsKura Oncology to Report Fourth Quarter and Full Year 2019 Financial Results
finance.yahoo.com - February 18 at 7:03 PM
Sushi Bar Parent Gets First Chance to Sell After 63% IPO SurgeSushi Bar Parent Gets First Chance to Sell After 63% IPO Surge
www.bloomberg.com - January 27 at 10:47 PM
Kura Oncology Announces Transition of Chief Medical OfficerKura Oncology Announces Transition of Chief Medical Officer
finance.yahoo.com - January 23 at 10:42 PM
Kura Oncology medical chief bids adieuKura Oncology medical chief bids adieu
seekingalpha.com - January 23 at 5:41 PM
Kura Oncology Announces Transition of Chief Medical OfficerKura Oncology Announces Transition of Chief Medical Officer
finance.yahoo.com - January 23 at 5:41 PM
Mitogen Activated Protein Kinase 1, Pipeline...Mitogen Activated Protein Kinase 1, Pipeline...
www.benzinga.com - January 20 at 11:18 AM
Kura Oncology (KURA) Presents At 38th Annual J.P. Morgan Healthcare Conference - SlideshowKura Oncology (KURA) Presents At 38th Annual J.P. Morgan Healthcare Conference - Slideshow
seekingalpha.com - January 17 at 1:33 PM
New commercial chief at Kura OncologyNew commercial chief at Kura Oncology
seekingalpha.com - January 6 at 12:24 PM
Kura Oncology Appoints Kirsten Flowers as Chief Commercial OfficerKura Oncology Appoints Kirsten Flowers as Chief Commercial Officer
finance.yahoo.com - January 6 at 12:24 PM
Kura Oncology Receives Fast Track Designation for Tipifarnib in HRAS Mutant HNSCC and Provides Enrollment Guidance for AIM-HN TrialKura Oncology Receives Fast Track Designation for Tipifarnib in HRAS Mutant HNSCC and Provides Enrollment Guidance for AIM-HN Trial
finance.yahoo.com - December 16 at 7:42 AM
Kura Oncology, Inc. (KURA): Hedge Funds Can’t Make Up Their MindsKura Oncology, Inc. (KURA): Hedge Funds Can’t Make Up Their Minds
finance.yahoo.com - December 10 at 2:36 PM
Kura Oncology Reports Clinical and Regulatory Updates for Tipifarnib in Angioimmunoblastic T-Cell LymphomaKura Oncology Reports Clinical and Regulatory Updates for Tipifarnib in Angioimmunoblastic T-Cell Lymphoma
finance.yahoo.com - December 8 at 1:33 PM
Kura Oncology to Participate in Piper Jaffray Healthcare ConferenceKura Oncology to Participate in Piper Jaffray Healthcare Conference
finance.yahoo.com - November 26 at 8:01 AM
Kura Oncology Requires Plenty of Patience by InvestorsKura Oncology Requires Plenty of Patience by Investors
finance.yahoo.com - November 25 at 3:16 PM
Kura Oncology Should Be On Your Radar With Upcoming Presentation For Cancer StudyKura Oncology Should Be On Your Radar With Upcoming Presentation For Cancer Study
seekingalpha.com - November 21 at 9:33 AM
Kura Oncology to Present at Stifel Healthcare ConferenceKura Oncology to Present at Stifel Healthcare Conference
finance.yahoo.com - November 12 at 9:24 AM
Hedge Funds Have Never Been This Bullish On Kura Oncology, Inc. (KURA)Hedge Funds Have Never Been This Bullish On Kura Oncology, Inc. (KURA)
finance.yahoo.com - November 9 at 5:28 PM
Kura Oncology Announces Upcoming Presentation at ASH Annual MeetingKura Oncology Announces Upcoming Presentation at ASH Annual Meeting
finance.yahoo.com - November 6 at 3:31 PM
Edited Transcript of KURA earnings conference call or presentation 5-Nov-19 9:30pm GMTEdited Transcript of KURA earnings conference call or presentation 5-Nov-19 9:30pm GMT
finance.yahoo.com - November 6 at 8:44 AM
Kura Oncology Reports Third Quarter 2019 Financial Results and Provides Corporate UpdateKura Oncology Reports Third Quarter 2019 Financial Results and Provides Corporate Update
finance.yahoo.com - November 5 at 6:26 PM
Kura Oncology Appoints James Basta as Chief Legal OfficerKura Oncology Appoints James Basta as Chief Legal Officer
finance.yahoo.com - November 4 at 8:38 AM
KURA Kura Oncology, Inc. Common StockKURA Kura Oncology, Inc. Common Stock
www.nasdaq.com - November 2 at 6:41 PM
Kura Oncology to Report Third Quarter 2019 Financial ResultsKura Oncology to Report Third Quarter 2019 Financial Results
finance.yahoo.com - October 30 at 8:35 AM
BRIEF-Kura Oncology Reports Durable Anti-Tumor Activity In Phase 2 Trial Of Tipifarnib In HRAS Mutant Head & Neck CancerBRIEF-Kura Oncology Reports Durable Anti-Tumor Activity In Phase 2 Trial Of Tipifarnib In HRAS Mutant Head & Neck Cancer
www.msn.com - October 29 at 11:44 PM
Kura Oncology Reports Durable Anti-Tumor Activity in Phase 2 Trial of Tipifarnib in HRAS Mutant Head and Neck CancerKura Oncology Reports Durable Anti-Tumor Activity in Phase 2 Trial of Tipifarnib in HRAS Mutant Head and Neck Cancer
finance.yahoo.com - October 29 at 1:44 PM
Kura Oncology Announces Upcoming Presentation at AACR-NCI-EORTC International Conference on Molecular Targets and Cancer TherapeuticsKura Oncology Announces Upcoming Presentation at AACR-NCI-EORTC International Conference on Molecular Targets and Cancer Therapeutics
finance.yahoo.com - October 16 at 6:36 PM
Kura Oncology Expands Board of Directors with Appointment of Diane ParksKura Oncology Expands Board of Directors with Appointment of Diane Parks
finance.yahoo.com - October 15 at 8:21 AM
Kura Oncology launches early-stage study of menin-MLL inhibitor for AMLKura Oncology launches early-stage study of menin-MLL inhibitor for AML
seekingalpha.com - September 16 at 12:02 PM
Kura Oncology Doses First Patient in Phase 1 Clinical Trial of Menin-MLL Inhibitor KO-539 in Acute Myeloid LeukemiaKura Oncology Doses First Patient in Phase 1 Clinical Trial of Menin-MLL Inhibitor KO-539 in Acute Myeloid Leukemia
finance.yahoo.com - September 16 at 8:00 AM
BRIEF-Kura Oncology Announces Positive Phase 2 Trial Of Tipifarnib In HRAS Mutant Urothelial CarcinomaBRIEF-Kura Oncology Announces Positive Phase 2 Trial Of Tipifarnib In HRAS Mutant Urothelial Carcinoma
www.msn.com - September 4 at 12:08 PM
Kuras tipifarnib shows positive effect in mid-stage bladder cancer studyKura's tipifarnib shows positive effect in mid-stage bladder cancer study
seekingalpha.com - September 3 at 10:46 AM
Kura Oncology Announces Positive Phase 2 Trial of Tipifarnib in HRAS Mutant Urothelial CarcinomaKura Oncology Announces Positive Phase 2 Trial of Tipifarnib in HRAS Mutant Urothelial Carcinoma
finance.yahoo.com - September 3 at 10:46 AM
Kura Oncology (KURA) Presents At Wedbush PacGrow Healthcare Conference - SlideshowKura Oncology (KURA) Presents At Wedbush PacGrow Healthcare Conference - Slideshow
seekingalpha.com - August 15 at 5:46 PM
Mitogen Activated Protein Kinase 1 Market Is Growing At an Exponential Rate in 2019 and Coming YearsMitogen Activated Protein Kinase 1 Market Is Growing At an Exponential Rate in 2019 and Coming Years
www.marketwatch.com - August 13 at 11:20 PM
New operating chief at Kura OncologyNew operating chief at Kura Oncology
seekingalpha.com - August 12 at 5:59 PM
Kura Oncology Announces Appointment of Kathleen Ford as Chief Operating OfficerKura Oncology Announces Appointment of Kathleen Ford as Chief Operating Officer
www.marketwatch.com - August 12 at 5:59 PM
Kura Oncology Announces Appointment of Kathleen Ford as Chief Operating OfficerKura Oncology Announces Appointment of Kathleen Ford as Chief Operating Officer
finance.yahoo.com - August 12 at 5:59 PM
Kura Oncology to Present at Wedbush PacGrow Healthcare ConferenceKura Oncology to Present at Wedbush PacGrow Healthcare Conference
finance.yahoo.com - August 7 at 10:40 AM
Edited Transcript of KURA earnings conference call or presentation 1-Aug-19 8:30pm GMTEdited Transcript of KURA earnings conference call or presentation 1-Aug-19 8:30pm GMT
finance.yahoo.com - August 5 at 6:06 PM
Kura Oncology, Inc. (KURA) 2019 Q2 Earnings Call TranscriptKura Oncology, Inc. (KURA) 2019 Q2 Earnings Call Transcript
finance.yahoo.com - August 3 at 8:33 AM
Kura Oncology, Inc. 2019 Q2 - Results - Earnings Call SlidesKura Oncology, Inc. 2019 Q2 - Results - Earnings Call Slides
seekingalpha.com - August 2 at 6:51 PM
This page was last updated on 4/5/2020 by MarketBeat.com Staff

Enter your email address below to receive a concise daily summary of analysts' upgrades, downgrades and new coverage with MarketBeat.com's FREE daily email newsletter.

Yahoo Gemini Pixel